Sun Pharmaceutical Industries and the Technion–Israel institute of technology have entered into an exclusive worldwide research and licence agreement for the development of novel anti-cancer drugs.
The joint project would be based on new findings by Nobel Prize laureate Professor Aaron Ciechanover, Gila Maor and Professor Ofer Binah, a note from Sun Pharma said.
The research development comes weeks after Sun sealed its $4-billion deal to merge troubled drugmaker Ranbaxy.
The institute’s pre-clinical research was funded this far by Dr Alfred Mann. The Technion and Sun Pharma alliance will advance this project through pre-clinical development process, said Ciechanover and Binah, adding that they had explored several alternatives in the past.